International Journal of Medicine and Data

Objective: To explore the clinical effect of droperithiaton melitracen combined with betahistine in the treatment of anxiety depression type psychogenic dizziness. Methods: 148 patients with psychogenic dizziness of anxiety depression type in our hospital from January 2019 to October 2020 were selected as the research objects. They were randomly divided into observation group and control group according to the principle of computer random number, with 74 cases in each group. The control group was treated with betahistine, and the observation group was treated with droperithiazide and melitracen combined with betahistine. The treatment effect, Hamilton Anxiety Scale (HAMA) score, Hamilton Depression Scale (HAMD) score, Comprehensive Quality of Life Rating Scale (CQOLI-74) score and adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of the observation group was 95.95%, which was significantly higher than that of the control group (72.97%, P<0.05); After treatment, the scores of HAMA and HAMD in the observation group were significantly lower than those in the control group, and the scores of CQOLI-74 were significantly higher than those in the control group (P<0.05). Conclusion: Flupentixol melitracen combined with betahistine is effective in the treatment of anxiety depression type psychogenic dizziness patients, which can significantly alleviate the clinical symptoms, improve the quality of life, and do not increase the incidence of adverse reactions.

Psychogenic dizziness of anxiety depression type; Flupentothiazide and melitracen; Betahistine